ADC Therapeutics SA (NYSE:ADCT) Shares Bought by XTX Topco Ltd

XTX Topco Ltd increased its position in ADC Therapeutics SA (NYSE:ADCT) by 129.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,863 shares of the company’s stock after acquiring an additional 32,034 shares during the period. XTX Topco Ltd owned approximately 0.07% of ADC Therapeutics worth $180,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. increased its stake in shares of ADC Therapeutics by 7.1% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 70,636 shares of the company’s stock valued at $317,000 after purchasing an additional 4,700 shares during the period. Sanibel Captiva Trust Company Inc. bought a new position in ADC Therapeutics in the 1st quarter worth approximately $462,000. Bank of New York Mellon Corp acquired a new stake in ADC Therapeutics in the 2nd quarter valued at approximately $648,000. Rhumbline Advisers acquired a new stake in ADC Therapeutics in the 2nd quarter valued at approximately $272,000. Finally, Acadian Asset Management LLC bought a new stake in ADC Therapeutics during the 2nd quarter valued at $51,000. 41.10% of the stock is currently owned by institutional investors.

ADC Therapeutics Price Performance

ADCT opened at $3.15 on Tuesday. ADC Therapeutics SA has a 1-year low of $0.36 and a 1-year high of $6.04. The company has a market capitalization of $260.75 million, a price-to-earnings ratio of -1.15 and a beta of 1.58. The business has a 50 day moving average price of $3.03 and a two-hundred day moving average price of $3.61.

ADC Therapeutics (NYSE:ADCT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. The firm had revenue of $17.41 million during the quarter, compared to analyst estimates of $19.06 million. During the same quarter last year, the company earned ($0.58) EPS. Equities analysts expect that ADC Therapeutics SA will post -1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ADCT. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research note on Thursday, August 8th. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 target price on shares of ADC Therapeutics in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

ADC Therapeutics Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.